Hepatic metastases of colorectal cancer: Locoregional intra-arterial treatment

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4785-4792

  Pasetto, Lara Maria ^a   Merenda, Roberto ^b   Pilati, Pierluigi ^c   Sinigaglia, Giulietta ^d   Monfardini, Silvio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Third Surgical Clinic   (Italy)

^c Second Surgical Clinic   (Italy)

^d CRO   (Italy)

Author keywords

Colorectal cancer; Intra arterial chemotherapy; Liver metastases; Review

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; MONOCLONAL ANTIBODY; OXALIPLATIN;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DIARRHEA; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN IRRITATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLOXURIDINE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 33845955821     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Berinan RS, Portera CA and Ellis LM: Biology of liver metastases. Cancer Treat Rev 109: 183-206, 2001.
2. Malafosse R, Penna Ch, Sa Cunha A and Nordlinger B: Surgical management of hepatic metastasis from colorectal malignancies. Ann Oncol 12(7): 887-894, 2001.
3. Vogl TJ, Muller PK, Mack MG, Straub R, Engelmann K and Neuhaus P: Liver metastases: interventional therapeutic techniques and results, state of the art. Radiol 9(4): 675-684, 1999.
4. Kemeny N, Daly J, Reichman B, Geller N, Botet J and Oderman P: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107: 459-465, 1987.
5. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M and Steinberg SM: A prospective randomised trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693, 1987.
6. Hohn DC, Stagg RJ, Friedman MA et al: A randomised trial of continuous i.v. versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1246-1654, 1989.
7. Wagman LD, Kemeney MM, Leong G et al: A prospective randomised evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8: 1885-1893, 1990.
8. Martin JK, O'Connel MJ, Wieand HS et al: intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: a randomised trial. Arch Surg 125: 1022-1027, 1990.
9. Lorenz M and Muller HH: Randomised, multicenter trial of fluorouracil plus leucovorin either via hepatic artery or intravenous infusion versus fluorodeoxyuridine administered via hepatic artery infusion in patients with non resectable liver metastases from colorectal carcinoma. J Clin Oncol 18(2): 243-254, 2000.
10. Harmantas A, Rostein LE and Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma liver metastatic to the liver. Cancer 78: 1639-1645, 1996.
11. The Meta-Analysis Group in Cancer: reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-258, 1996.
12. Rougier P, Laplanche A, Hoguier M et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomised trial. J Clin Oncol 10(7): 1112-1118, 1992.
13. Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344(8932): 1255-1260, 1994.
14. Kemeny N, Conti JA, Cohen A et al: Phase II study of hepatic arterial floxuridine, leucovorin and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12: 2288-2295, 1994.
15. O'Connell MJ, Nagorney DM, Bernath AM et al: Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 16(7): 2528-2533, 1998.
16. Porta C, Danova M, Accurso S et al: Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. Cancer Chemother Pharmacol 47(5): 423-428, 2001.
17. Mancini R, Tedesco M, Garufi C et al: Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res 23(2C): 1837-1841, 2003.
18. Kemeny N, Gonen M, Sullivan D et al: Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19: 2687-2695, 2001.
19. Kemeny N, Jarnagin W, Paty P et al: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23: 4888-4896, 2005.
20. Fordy C, Glover C, Davies MM and Allen-Mersh TG: Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br J Cancer 78(8): 1058-1060, 1998.
21. Kemeny N, Huang Y, Cohen AM et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastasis from colorectal cancer. New Engl J Med 341(27): 2039-2048, 1999.
22. Kemeny MM, Adak S, Gray B et al: Combined modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastasis in combination with continuous infusion of chemotherapy - an Intergroup Study. J Clin Oncol 20: 1499-1505, 2002.
23. Kemeny N, Jarnagin W, Gonen M et al: Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 21(17): 3303-3309, 2003.
24. Litvak DA, Wood TF, Tsioulias GJ et al: Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol 9(2): 148-155, 2002.
25. Copur MS, Capadano M, Lynch J et al: Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol 19(9): 2404-2412, 2001.
26. Pancera G, Garassino MC, Beretta GD et al: A feasibility study of combined hepatic arterial infusion (HAI) with FUDR and systemic chemotherapy (SYS) with FOLFOX 4 in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 21: 105 (abs 2233), 2002.
27. Borner M, Laffer U, Ludwig C et al: Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. The Swiss Group for Clinical and Epidemiological Cancer Research (SAKK). Ann Oncol 1(3): 227-228, 1990.
28. Staib-Sebler E, Lorenz M, Gog C et al: Continuous arterial 5-fluorouracil and folinic acid chemotherapy for colorectal liver metastases. Onkologie 78: 240-244, 1995.
29. Howell JD, McArdle CS, Kerr DJ et al: A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. Br J Cancer 76: 1390-1393, 1997.
30. Howell JD, Warren HW, Anderson JH, Kerr DJ and McArdle CS: Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer. Eur J Surg 165(7): 652-658, 1999.
31. Lorenz M, Mueller HH, Mattes E et al: German Cooperative Group on Liver Metastases (Arbeitsgruppe Lebermetastasen und -tumoren (ALM) in der Chirurgischen Arbeitsgemeinschaft Onkologie): Phase II study of weekly 24-h intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. Ann Oncol 12(3): 321-325, 2001.
32. Muller B, Nakchbandi W, Chatzissavvidis I and Valek V: Intraarterial infusion of 5FU plus granocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. Eur J Surg Oncol 27(7): 652-661, 2001.
33. Lorenz M, Muller H, Schramm H et al: Randomised trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228: 756-764, 1998.
34. Ishibashi K, Yoshimatsu K, Yokomizo H et al: Low-dose leucovorin and 5-Fluorouracil for unresectable multiple liver metastasis from colorectal cancer. Anticancer Res 25(6C): 4747-4752, 2005.
35. Tono T, Hasuike Y, Ohzato H, Takatsuka Y and Kikkawa N: Limited but definite efficacy of prophylactic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomised study. Cancer 88(7): 1549-1556, 2000.
36. Melirhar B, Dvorak J, Jandik P et al: Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases - a pilot experience. Hepatogastroenterol 48(42): 1721-1726, 2001.
37. Van Riel JM, Van Groeningen CI, Kedde MA et al: Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 8(2): 405-412, 2002.
38. Hofmann C, Buttenschoen K, Straeter J, Henne-Bruns D and Kornmann M: Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. Anticancer Res 25(2A): 795-804, 2005.
39. Neyns B, Fontaine C, Delvaux G, Di Betta D and De Greve J: Efficacy of hepatic arterial infusion of CPT11 and MTX modulated 5-fluorouracil for patients with colorectal cancer metastatic to the liver after failure of systemic thymidylate-synthase inhibitor treatment. Proc Am Soc Clin Oncol 21: 122 (abs 2301), 2002.
40. Tanaka K, Adam R, Giacchetti S et al: intra-arterial hepatic infusion of circadian chronotherapy with irinotecan, 5-fluorouracil and oxaliplatin against liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 21: 122 (abs 2303), 2002.
41. Tomirotti M, Bobbio Pallavicini E, Tacconi F et al: First-line activity of hepatic arterial infusion (HAI) of oxaliplatin and systemic chemotherapy with leucovorin plus 5-fluorouracil in metastatic colorectal cancer: preliminary data of a multicenter study. Proc Am Soc Clin Oncol 21: 135 (abs 2353), 2002.
42. Ducreux M, Ychou M, Laplanche A et al: Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23(22): 4881-4887, 2005.
43. Moosmann N, Kern W, Waggershauser T, Hiddemann W, Heinemann V and Schalhorn A: Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer, final analysis of a phase I-/II-study. Proc Am Soc Clin Oncol 24: abs 3628, 2005.
44. Kuramochi H, Hayashi K, Uchida K et al: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12(1): 29-33, 2006.
45. Boige V, Malka D and Ducreux M: Therapeutic strategies using VEGF inhibitors in colorectal cancer. Bull Cancer 92(S2): 29-36, 2005.
46. Salesi N, Bossone G, Veltri E et al: Clinical experience with bevacizumab in colorectal cancer. Anticancer Res 25(5): 3619-3623, 2005.
47. Adenis A and Hebbar M: Targeting the epidermal growth factor receptor in colorectal cancer: clinical results. Bull Cancer 92 Suppl 2: 21-28, 2005.
48. Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK and Monfardini S: FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 25(1B): 563-576, 2005.